Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp.
Your view on MDNA.TO
Overview
What the company does, where it operates, and who runs it.
About Medicenna Therapeutics Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Fahar Merchant
- Headquarters
- 2 Bloor Street West, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Fahar Merchant
- Headquarters
- 2 Bloor Street West, Toronto, ON, CA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors.
In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Medicenna Therapeutics Corp., and the rating behind it. MDNA.TO last traded at C$0.41; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Medicenna Therapeutics Corp.. Starting points for Medicenna Therapeutics Corp.: EPS -C$0.21, beta 1.93 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Medicenna Therapeutics Corp.. Medicenna Therapeutics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Medicenna Therapeutics Corp.. Trailing twelve-month EPS for Medicenna Therapeutics Corp. stands at -C$0.21. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Medicenna Therapeutics Corp.. Medicenna Therapeutics Corp. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Medicenna Therapeutics Corp. valued side by side against its closest peers. Medicenna Therapeutics Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Medicenna Therapeutics Corp., and how their positions are changing. At a C$32.2M market value, institutional positions materially move Medicenna Therapeutics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Medicenna Therapeutics Corp. executives and directors. Shares of Medicenna Therapeutics Corp. have traded between C$0.78 and C$2.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Medicenna Therapeutics Corp.. Medicenna Therapeutics Corp. is a C$32.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Medicenna Therapeutics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Medicenna Therapeutics Corp.. Coverage tracks Medicenna Therapeutics Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.